894. Trend of Transmitted Resistance Associated Mutations in People Living with HIV (PLWH) in a Large Southeastern U.S. Ryan White Clinic

por Kavouklis, Alisha, Ladak, Amber F, Hamilton, Caroline, Mims, Annastesia, Askar, Gina, Newman, Cheryl
Publicado 2021

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80

por Kumar, Princy N, Goldstein, Deborah A, Hengel, Richard L, Gaur, Aditya H, Wurapa, Anson K, Khalsa, Ann M, Newman, Cheryl L, Saunders, Gary, Liu, Shan-Yu, Dvory-Sobol, Hadas, Rhee, Martin, Gupta, Samir K
Publicado 2023

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results...

por Mills, Anthony, Richmond, Gary J, Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Andany, Nisha, Margolis, David, Sutton, Kenneth, Wilches, Viviana, Roberts, Jeremy, McCoig, Cynthia C, Vandermeulen, Kati, Spreen, William
Publicado 2020

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

por Mills, Anthony, Richmond, Gary J., Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Margolis, David A., Sutton, Kenneth C., Wilches, Viviana, Hatch, Sarah, Roberts, Jeremy, McCoig, Cynthia, Garris, Cindy, Vandermeulen, Kati, Spreen, William R.
Publicado 2022